BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 32442903)

  • 1. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
    Shu C; Li Q
    Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
    Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
    Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
    Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
    Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
    J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
    Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
    Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
    Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
    J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated microenvironment, PD-L1 expression and their relationship with immunotherapy in glioblastoma, IDH-wild type: A comprehensive review with emphasis on the implications for neuropathologists.
    Broggi G; Angelico G; Farina J; Tinnirello G; Barresi V; Zanelli M; Palicelli A; Certo F; Barbagallo G; Magro G; Caltabiano R
    Pathol Res Pract; 2024 Feb; 254():155144. PubMed ID: 38277747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid tumor recurrence in a novel murine GBM surgical model is associated with Akt/PD-L1/vimentin signaling.
    Liu F; Xu XH; Li CY; Zhang TT; Yin SL; Liu GQ; Hu F; Yu SB; Chen XQ
    Biochem Biophys Res Commun; 2021 Sep; 569():1-9. PubMed ID: 34216991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
    Zhang P; Miska J; Lee-Chang C; Rashidi A; Panek WK; An S; Zannikou M; Lopez-Rosas A; Han Y; Xiao T; Pituch KC; Kanojia D; Balyasnikova IV; Lesniak MS
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23714-23723. PubMed ID: 31712430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
    Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
    Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of tumor immune environment between newly diagnosed and recurrent glioblastoma including matched patients.
    Wang F; Cathcart SJ; DiMaio DJ; Zhao N; Chen J; Aizenberg MR; Shonka NA; Lin C; Zhang C
    J Neurooncol; 2022 Aug; 159(1):163-175. PubMed ID: 35754074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1/PD-1 Axis in Glioblastoma Multiforme.
    Litak J; Mazurek M; Grochowski C; Kamieniak P; Roliński J
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
    Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
    Front Immunol; 2018; 9():727. PubMed ID: 29910795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape.
    Mohme M; Maire CL; Schliffke S; Joosse SA; Alawi M; Matschke J; Schüller U; Dierlamm J; Martens T; Pantel K; Riethdorf S; Lamszus K; Westphal M
    Acta Neuropathol Commun; 2020 Mar; 8(1):28. PubMed ID: 32151286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
    Shida Y; Nakazawa T; Matsuda R; Morimoto T; Nishimura F; Nakamura M; Maeoka R; Yamada S; Nakagawa I; Park YS; Yasukawa M; Tojo T; Tsujimura T; Nakase H
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
    Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint-Blocking Nanocages Cross the Blood-Brain Barrier and Impede Brain Tumor Growth.
    Kim M; Yoon HJ; Lee C; Lee M; Park RW; Lee B; Park EJ; Kim S
    ACS Biomater Sci Eng; 2024 Jan; 10(1):575-587. PubMed ID: 38150627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.